RT Journal Article SR Electronic T1 Differences in the Therapeutic Effect of Chemotherapy Regimens for Concurrent Chemoradiotherapy of Locally Advanced Non-small Cell Lung Cancer JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1073 OP 1079 DO 10.21873/anticanres.15569 VO 42 IS 2 A1 MINORU HORIUCHI A1 TETSUYA OGURI A1 YUSUKE KAGAWA A1 KAZUKI SONE A1 SATOSHI FUKUDA A1 TAKEHIRO UEMURA A1 OSAMU TAKAKUWA A1 KEN MAENO A1 KENNSUKE FUKUMITSU A1 YOSHIHIRO KANEMITSU A1 TOMOKO TAJIRI A1 HIROTSUGU OHKUBO A1 MASAYA TAKEMURA A1 YUTAKA ITO A1 AKIO NIIMI YR 2022 UL http://ar.iiarjournals.org/content/42/2/1073.abstract AB Background/Aim: The optimal chemotherapy for concurrent chemoradiotherapy (cCRT) of lung cancer is still unclear. Patients and Methods: We investigated the therapeutic effect of different chemotherapy regimens for cCRT of lung cancer in 65 patients at our hospital. Results: Of the 65 patients, 53 were male and 12 female. The median age was 64 years and 58 participants had a smoking history. The histological type was adenocarcinoma in 34 cases, squamous cell carcinoma in 22 cases, and others in 9 cases. Induction therapy consisted of cisplatin plus vinorelbine (CDDP+VNR) in 50 cases, and weekly carboplatin plus paclitaxel (CBDCA+PTX) in 15 cases. In all patients, the overall response rate, disease control rate, median progression survival, and median overall survival were 78.5%, 95.4%, 337 days, and 1,037 days, respectively. The median progression-free survival was 337 days in total; it was significantly longer for CDDP+VNR than CBDCA+PTX. The median overall survival was 1,037 days in total; it tended to be slightly longer for CDDP+VNR than CBDCA+PTX. Conclusion: Different chemotherapy regimens for cCRT possibly have different therapeutic effects.